Patents Assigned to Seikagaku Corporation
  • Publication number: 20240398712
    Abstract: There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.
    Type: Application
    Filed: August 12, 2024
    Publication date: December 5, 2024
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Mine HIGUCHI
  • Publication number: 20240390411
    Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: August 8, 2024
    Publication date: November 28, 2024
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Tomochika KISUKEDA, Yasuhiro GOTO, Yuichi CHIKARAISHI, Takahiro HATANAKA
  • Patent number: 12090228
    Abstract: There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: September 17, 2024
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Mine Higuchi
  • Patent number: 11959109
    Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.
    Type: Grant
    Filed: July 3, 2023
    Date of Patent: April 16, 2024
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Hikaru Mizumura, Toshio Oda, Shun-ichiro Kawabata
  • Patent number: 11944670
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: April 2, 2024
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Publication number: 20230357742
    Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.
    Type: Application
    Filed: July 3, 2023
    Publication date: November 9, 2023
    Applicant: Seikagaku Corporation
    Inventors: Hikaru MIZUMURA, Toshio Oda, Shun-Ichiro Kawabata
  • Patent number: 11779593
    Abstract: Provided is an agent for improving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: October 10, 2023
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Masamichi Yamada, Chiyo Sakenaga, Keiichiro Arai, Kazutaka Yamamoto
  • Patent number: 11744899
    Abstract: Provided is a method for suppressing the generation of diclofenac lactam from a compound represented by a formula (1) in the description, including allowing the compound of the formula (1) and a component (A) that is at least one type of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 mono-alcohol, a C2 to C3 di-alcohol, a C3 to C6 tri-alcohol, a polyalkylene glycol, a ?-lactone, polyvinylpyrrolidone, a chlorogenic acid, and an alkyl sulfate ester, and salts thereof to coexist. A method for producing a pharmaceutical composition containing a compound represented by the formula (1) and a component (A), and a pharmaceutical composition which is a product produced thereby are also provided.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 5, 2023
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Chiaki Takahata, Naoya Yamashita, Naoko Kunii, Hirotaka Hoshi
  • Patent number: 11738040
    Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: August 29, 2023
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Kazuyuki Kano, Yuji Nobuoka, Takayuki Seo
  • Publication number: 20230263871
    Abstract: A pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/?g as an active ingredient, and contains the saccharide-degrading enzyme in an amount of not less than 2 ?g and not more than 6 ?g.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 24, 2023
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Mine HIGUCHI
  • Publication number: 20230193349
    Abstract: Provided is a technology related to a horseshoe crab factor B variant, and also provided is means for performing endotoxin measurement with high sensitivity. A polypeptide having an amino acid sequence in which the amino acid residue at the 193-position in an amino acid sequence of a polypeptide of horseshoe crab factor B is substituted with a cysteine (Cys) residue, is produced. Endotoxin measurement can be carried out with high sensitivity by configuring a Limulus reagent by combining this polypeptide with horseshoe crab factor C.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 22, 2023
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Yuki KOBAYASHI, Hikaru MIZUMURA, Toshio ODA, Shun-ichiro KAWABATA
  • Patent number: 11648299
    Abstract: There are provided a pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/?g as an active ingredient, and containing the saccharide-degrading enzyme in an amount of not less than 2 ?g and not more than 8 ?g.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: May 16, 2023
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Mine Higuchi
  • Publication number: 20230136938
    Abstract: An object of the present invention is to find a useful means for removing an intraocular membrane. The present invention relates to an agent for use in intraocular membrane peeling surgery, which contains a solution containing a hydrogel-forming material and satisfies the following formula 1 with respect to the dynamic viscoelasticity measured at a temperature of 25 to 40° C. and a frequency of 1 Hz. 0<Vmax?3??(Formula 1) Provided that in the formula 1, Vmax (Pa/sec) is the maximum change rate of the storage elastic modulus after the initiation of gelation.
    Type: Application
    Filed: March 24, 2021
    Publication date: May 4, 2023
    Applicants: FUKUOKA UNIVERSITY, SEIKAGAKU CORPORATION
    Inventors: Toshio HISATOMI, Kiyoshi SUZUKI
  • Publication number: 20220370630
    Abstract: As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 24, 2022
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Muneto NARITA, Kensuke ISHII, Akihito SHIMURA
  • Patent number: 11499177
    Abstract: Provided is a technology related to a horseshoe crab factor B variant, and also provided is means for performing endotoxin measurement with high sensitivity. A polypeptide having an amino acid sequence in which the amino acid residue at the 193-position in an amino acid sequence of a polypeptide of horseshoe crab factor B is substituted with a cysteine (Cys) residue, is produced. Endotoxin measurement can be carried out with high sensitivity by configuring a Limulus reagent by combining this polypeptide with horseshoe crab factor C.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: November 15, 2022
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Yuki Kobayashi, Hikaru Mizumura, Toshio Oda, Shun-Ichiro Kawabata
  • Publication number: 20220296634
    Abstract: The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. The present invention also relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, sorbitol, and a pharmaceutical acceptable carrier.
    Type: Application
    Filed: June 7, 2022
    Publication date: September 22, 2022
    Applicant: Seikagaku Corporation
    Inventors: Eiji NOGAMI, Akira KOUSHINBOU, Noriko OSHIMA, Kota FUJIWARA, Tomoya SATO
  • Publication number: 20220257781
    Abstract: Provided is a compound as a compound obtained by conjugating a tertiary amine compound or an imine compound, which is useful as a drug, with a polymer, in which a structure D+ forming a quaternary ammonium salt or an iminium salt from D, a tertiary amine compound or an imine compound and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R1)(R2)OC(?O)YANHC(?O)—.
    Type: Application
    Filed: September 5, 2019
    Publication date: August 18, 2022
    Applicant: Seikagaku Corporation
    Inventors: Nobuo Kobayashi, Kenichi Namatsu
  • Publication number: 20220145280
    Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 12, 2022
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Hikaru MIZUMURA, Toshio ODA, Shun-ichiro KAWABATA
  • Publication number: 20220133776
    Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Tomochika KISUKEDA, Yasuhiro GOTO, Yuichi CHIKARAISHI, Takahiro HATANAKA
  • Patent number: D1037440
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 30, 2024
    Assignees: TAISEI KAKO CO., LTD., SEIKAGAKU CORPORATION
    Inventors: Takuya Suzuki, Shota Masuda, Ippei Matsumoto, Yosuke Ikoma